Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Biochemical Differences among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture

Huey-Jane Lee, Katarzyna Pawlak, Binh T. Nguyen, Roland K. Robins and Wolfgang Sadée
Huey-Jane Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarzyna Pawlak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Binh T. Nguyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland K. Robins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Sadée
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 1985
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The mechanism of the cellular toxicity of four inosinate dehydrogenase (IMP-DH) inhibitors with different antitumor and antiviral pharmacological profiles was investigated in mouse lymphoma (S-49) cell culture. Drug effects on cell growth, nucleotide pools, and DNA and RNA synthesis were measured in the presence and absence of guanine salvage supplies. Both guanine and guanosine were capable of bypassing the IMP-DH block, while they also demonstrated some growth-inhibitory effects when added alone in high concentrations. All four drugs reduced cellular guanosine triphosphate levels and caused secondary changes of the uridine, cytidine, and adenosine triphosphate pools that were similar among the four drugs. However, several drug effects in addition to IMP-DH inhibition were observed except with mycophenolic acid which may represent a pure IMP-DH inhibitor. Both tiazofurin and selenazofurin interfered with the uptake and/or metabolism of uridine and thymidine tracers; however, this effect appeared not to contribute to their cellular toxicity in vitro. Moreover, selenazofurin and tiazofurin impaired the utilization of exogenous guanine salvage supplies for DNA and RNA synthesis, and guanine was particularly ineffective in reversing the toxic effects of tiazofurin on cell growth. This finding is important in view of the available guanine salvage supplies in vivo. Since tiazofurin, selenazofurin, and their known metabolites failed to inhibit hypoxanthine-guanine-phosphoribosyl transferase, guanosine monophosphate kinase, and guanosine diphosphate kinase in cell extracts or permeabilized cells, these drugs may interfere with salvage transport across cellular membranes. The toxic effects of mycophenolic acid and ribavirin were similarly reversed by salvage supplies of up to 200 µm guanine, which suggests that ribavirin primarily acts as an IMP-DH inhibitor under these conditions. This result could explain the rather low antitumor efficacy of both mycophenolic acid and ribavirin in vivo. However, increasing the guanine salvage supply in the medium above 200 µm further reversed the toxic effects of mycophenolic acid to maximum rescue, while it increased the toxicity of ribavirin (300 µm). This finding suggests the presence of a toxic mechanism of ribavirin at higher concentrations that is dependent upon the presence of guanine supplies sufficient to fully overcome the IMP-DH inhibition. This study documents that each antimetabolite displays a unique spectrum of activities with multiple toxic targets.

Footnotes

  • ↵1 This research was supported by USPHS Grants CA-27866, CA 34304, and CA-34384 from the National Cancer Institute.

  • ↵2 To whom requests for reprints should be addressed.

  • Received September 10, 1984.
  • Revision received July 3, 1985.
  • Accepted July 8, 1985.
  • ©1985 American Association for Cancer Research.
PreviousNext
Back to top
November 1985
Volume 45, Issue 11 Part 1
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Biochemical Differences among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biochemical Differences among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture
Huey-Jane Lee, Katarzyna Pawlak, Binh T. Nguyen, Roland K. Robins and Wolfgang Sadée
Cancer Res November 1 1985 (45) (11 Part 1) 5512-5520;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Biochemical Differences among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture
Huey-Jane Lee, Katarzyna Pawlak, Binh T. Nguyen, Roland K. Robins and Wolfgang Sadée
Cancer Res November 1 1985 (45) (11 Part 1) 5512-5520;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Basic Sciences

Articles

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement